← All insights
HERMS · INSIGHTS

Agentic AI vs. Generative AI in Pharmaceuticals: Key Differences and Applications

Global life sciences AI · Published 16 November 2026 · HERMS Consultancy DMCC

Discover the HERMS life sciences platform and our regulatory affairs expertise.

Generative AI produces content or structured outputs, such as a scientific summary or extracted data. Agentic AI coordinates goal-directed, multi-step work through planning, tools and feedback, potentially acting across connected systems. An agent may use a generative model as one component alongside rules, workflow software and human review. In pharmaceuticals, the appropriate choice depends on the task, evidence, action permissions and consequences. Neither architecture inherently guarantees reliability, data integrity or regulatory compliance; those qualities depend on the implemented system and its controls. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework

1. The difference is workflow responsibility

The practical question in agentic AI vs generative AI in pharmaceuticals is not which label is more advanced. It is whether the organization needs an answer, a repeatable transaction or an orchestrated sequence of work. A medical-writing assistant can summarize an approved study report without owning the surrounding process. An agent may retrieve updated evidence, compare it with the draft, propose edits and route a review task. A rules engine can reject a missing mandatory field without generating language. These are functional distinctions, not separate regulatory categories.

Agentic does not necessarily mean autonomous. An agent can stop at every approval gate, while a simple deterministic program can execute automatically. Conversely, a generative application can call tools without being granted responsibility for a long-running workflow. Assess the actual configuration: what it can read, infer, write and trigger. This operational view is consistent with evaluating risk by intended use and context rather than by product branding. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products AI Risk Management Framework

2. How the architecture works

A foundation model is trained on broad data and can be adapted to different tasks. A large language model, or LLM, is a language-focused example. Prompts provide instructions and context; they are not a substitute for access controls or an executable specification. Model outputs are probabilistic in the sense that learned patterns drive generation. Making decoding more repeatable does not establish factual accuracy or scientific validity. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile

Retrieval-augmented generation, or RAG, supplies retrieved evidence to a model at run time. In RAG pharmaceutical AI, preserve document identity, version, date and source location. Retrieval may improve grounding, but outdated sources, poor chunking, missed documents or incorrect interpretation still produce unreliable answers. A displayed citation must actually support the associated claim; the presence of a hyperlink is not proof of fidelity. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile

Tools and APIs connect the application to repositories and operational systems. Function calling lets a model propose a structured tool invocation; application code must validate the arguments and authorize execution. A workflow engine manages sequence, queues, retries and exceptions. A rules engine enforces explicit conditions such as required fields or routing thresholds. Deterministic components follow defined logic for given inputs; they can still fail because of defective rules, bad data or integration faults.

Memory or state stores task progress and relevant context across steps. It needs ownership, retention limits and protection against cross-product or cross-customer contamination. Evaluators test selected output qualities; observability exposes execution events and failures. Approval gates connect decisions to accountable people. A sensible reference architecture is therefore approved sources → retrieval → model-assisted analysis → deterministic checks → permitted tool calls → review → monitored execution. This is a proposed design pattern, not a claim about a validated HERMS implementation. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework OWASP GenAI Security Project

3. Core technology comparison

DimensionGenerative AIAgentic AITraditional rules
PurposeProduce or transform contentCoordinate goal-directed workExecute explicit logic
Unit of workResponse or structured outputMulti-step task with stateRule, transaction or fixed flow
Workflow ownershipUsually bounded assistanceMay coordinate sequence and routingPredefined process paths
Tool accessOptionalCommon; permission-limitedProgrammed integrations
State / memoryOptional contextTask state often persistentExplicit records and variables
Human interactionPrompt, inspect, editSet goal, approve, superviseConfigure, handle exceptions
ResultText, code or extracted fieldsOutputs plus proposed/executed actionsSpecified output or action
AdaptabilityFlexible language interpretationDynamic step selection within boundsNew cases require explicit logic
Failure modesFabrication, omission, biasModel errors plus cascading tool errorsFaulty rules, bad inputs, brittle paths
EvaluationFidelity and task accuracyEnd-to-end outcomes and permissionsRule coverage and correctness
AuditabilityCapture sources and versionsAlso capture calls, state and approvalsCapture logic, inputs and transactions
Security boundaryInput, context and generated outputAlso identities, tools and external effectsApplication and integration privileges
ComplexityVariable; grows with grounding needsOften higher operational complexityOften simpler for stable bounded tasks

This comparison describes common patterns, not absolute boundaries. All three approaches can use databases, APIs and human approval. A hybrid is often preferable when flexible language interpretation must feed a controlled operational process. The objective is to allocate uncertainty to a component that can be checked, while keeping authorization outside model-generated text. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework

4. Pharmaceutical use-case selection matrix

The following matrix is a proposed selection aid, not a regulatory authorization. “Hybrid” means a combination of generative analysis, bounded orchestration, deterministic controls and accountable review. No entry authorizes independent legally reserved sign-off. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle EudraLex — Volume 4 — Good Manufacturing Practice guidelines ICH E6 Good clinical practice

Use caseBest fitDesired outputEssential controlOperational constraint
Medical writingGenAIEvidence-linked draftScientific review; source fidelityOnly approved evidence
Regulatory intelligenceHybridVerified change and impact tasksSource and applicability reviewJurisdiction/product scope
Dossier assemblyHybridMapped, consistent packageVersion control; filing approvalPublishing specifications
Literature surveillanceHybridPrioritized evidence queueCoverage checks; verified citationsDatabase access and rights
Adverse-event intakeHybridCandidate fields and triage taskPreserve original; qualified reviewReporting clocks and language
Signal analysisHybridPatterns and evidence summariesSafety evaluation; statistical checksIncomplete or biased reports
Protocol draftingGenAIDesign alternatives and draftClinical/statistical reviewScientific and ethics constraints
Trial site monitoringHybridRisk flags and review tasksSponsor oversight; data checksAccess and site context
CGT evidence mappingHybridLinked scientific evidence mapSpecialist verificationSensitive genomic/process data
Deviation / CAPAHybridInvestigation evidence and proposalsQuality approval of conclusionsCausality needs investigation
Batch reviewHybridRecord checks and exceptionsRequired authorized release retainedValidated records and interfaces
Supply forecastingHybridForecast from predictive model plus explanationBacktesting; planner reviewPredictive model/data quality
Device change managementHybridChange assessment and test tasksManufacturer regulatory assessmentIntended use; approved change scope

Supply forecasting illustrates an important boundary: prediction may rely on conventional statistical or machine-learning models, while generative AI explains results and an agent coordinates data collection. Not every useful pharmaceutical AI capability is generative. Use deterministic rules for stable arithmetic, mandatory-field checks and access decisions rather than asking a model to improvise them.

5. Two hypothetical end-to-end workflows

Example A: regulatory intelligence to approved dossier tasks

Hypothetical workflow: a scheduled connector detects a changed authority publication. Rules preserve its URL, publication metadata and prior version. An agent retrieves the relevant text, compares changes and proposes affected products and dossier sections. A regulatory specialist verifies the primary source, effective date, transition provisions and actual applicability before approving tasks. The workflow then creates only those tasks approved for the specified product and destination.

Hallucination can invent a requirement; missing context can confuse a draft with final guidance; a tool error can attach work to the wrong product. Controls include source excerpts, explicit unknowns, product identifiers, duplicate prevention and approval tied to the precise task payload. If a source is inaccessible, the system should route an exception rather than infer the missing obligation. This example proposes controls; it is not a reported deployment. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile

Example B: literature screening to accountable safety assessment

Hypothetical workflow: an approved search retrieves literature, a screening component flags a possible case and rules check candidate fields and potential duplicates. A bounded agent prepares a provisional case record and urgent triage task. Safety personnel check the full text, resolve missing information and conduct the appropriate assessment. Where reporting is required, a controlled process manages authorization, transmission and acknowledgement according to applicable procedures.

A model may misread negation, miss an event in a table or confuse the study population with an individual report. Missing context can distort chronology; tool retries can create duplicate records. Preserve the original evidence, label extracted fields as candidates, make retries idempotent and monitor urgent queues. Do not equate automated screening with medical assessment, and do not let review delays defeat applicable reporting timelines. These are proposed safeguards, not a universal requirement for manual approval of every case. Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile

6. Which AI approach should we deploy?

Use this decision tree before selecting a vendor or architecture:

  • Is the task repeatable with explicit, stable conditions? Start with rules. Add AI only where interpreting variable evidence is necessary.
  • Is the requirement primarily a draft, summary or extraction? Start with bounded GenAI and verified sources.
  • Must the system coordinate multiple steps or act through tools? Consider agentic orchestration; a fixed sequence may still need only a workflow engine.
  • Are data sensitive, or could errors affect patients, products or regulated records? Restrict sources and environments, assess risk and narrow action rights.
  • Is the action hard to reverse? Require stronger pre-execution checks and applicable human sign-off rather than relying only on monitoring.
  • Can the evidence and action be reconstructed? If not, redesign the audit trail before production.
  • Does verification consume the expected benefit? Measure total review and rework, not merely generation speed.
  • Can the process fall back to deterministic checks or manual handling? If not, define a safe stop and escalation route before deployment.

Choose the simplest architecture that meets the acceptance criteria. Longer workflows create more opportunities for context loss, integration failure and cascading error. Added autonomy is justified only when its incremental operational value exceeds its verification, security and maintenance burden. This is a practical selection principle, not an asserted numerical ROI. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework

7. Risks, security and safeguards

Hallucinated citations require source-to-claim verification, not a request to “be accurate.” Prompt injection occurs when untrusted content attempts to redirect the system; treat retrieved documents and tool responses as data, not authority. Tool misuse and over-permissioned agents can turn interpretation errors into record changes or disclosure. Enforce least privilege in application code, isolate service identities and allowlist actions and destinations. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile OWASP GenAI Security Project

Protect sensitive clinical, personal, genomic and commercial data across prompts, retrieval, memory, logs and provider arrangements. Apply segregation of duties: the component proposing a consequential action should not grant itself permission. Maintain cybersecurity controls, monitoring, rollback where feasible and exception escalation. For irreversible external actions, prevention and approval matter more than a promise to undo them. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile OWASP GenAI Security Project

Model drift, source changes and configuration updates can invalidate earlier evaluation. Control versions of models, prompts, indexes, tools and rules; assess changes and rerun relevant tests. Human review also needs testing: reviewers require usable evidence, sufficient time and authority to reject outputs. Combining an LLM, rules and governance is a deliberate control architecture, not an admission that the technology has failed. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework

8. GxP implications and validation

Not every AI application is automatically a GxP system. Determine intended use, regulated activity, records relied upon and possible impact on patient safety, product quality and data integrity. A brainstorming assistant and a system preparing evidence used in batch disposition have different assurance needs. Validation or assurance should demonstrate fitness for the configured use, not declare a foundation model universally compliant. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products EudraLex — Volume 4 — Good Manufacturing Practice guidelines Part 11, Electronic Records; Electronic Signatures — Scope and Application

Use ALCOA+ as a data-integrity design lens: attributable, legible, contemporaneous, original and accurate, plus complete, consistent, enduring and available. In practice, preserve originals, identify who or what created an entry, record timestamps and changes, and retain usable evidence. These concepts do not make every conversational exchange a regulated record; the applicable activity and record obligations determine the boundary. EudraLex — Volume 4 — Good Manufacturing Practice guidelines Part 11, Electronic Records; Electronic Signatures — Scope and Application

Assess 21 CFR Part 11 where applicable to electronic records and signatures, including underlying predicate rules. FDA’s scope guidance is nonbinding and describes limited enforcement discretion; Part 11 remains in effect. EU GMP Annex 11 addresses computerized systems, while GCP expectations apply to relevant trial activities. In the EU, ICH E6(R3) Principles and Annex 1 became effective on 23 July 2025; Annex 2 becomes effective on 15 January 2027. Implementation dates differ internationally. EudraLex — Volume 4 — Good Manufacturing Practice guidelines ICH E6 Good clinical practice Part 11, Electronic Records; Electronic Signatures — Scope and Application

9. Regulatory landscape as of 16 November 2026

FDA’s January 2025 guidance on AI supporting drug/biologic regulatory decision-making is still labelled draft and not for implementation on the verified official page. It proposes a risk-based credibility framework for a specified context of use. EMA’s medicinal-product lifecycle reflection paper was adopted and first published on 30 September 2024. Neither document establishes that agentic architecture itself confers regulatory acceptability. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle

The EU AI Act is binding legislation with a risk-based scope; do not label every pharmaceutical assistant high-risk. The Commission’s current page states general application from 2 August 2026, with AI-literacy/prohibition provisions from 2 February 2025 and GPAI rules from 2 August 2025. It reports AI Omnibus entry into force on 27 July 2026 and revised high-risk dates of 2 December 2027 for Annex III and 2 August 2028 for Annex I product-related systems. These dates are verified against the Commission summary; the operative amended legal text was not retrievable through the supplied EUR-Lex route, so legal reliance requires a final text check. AI Act

NIST AI RMF and its Generative AI Profile are voluntary resources, not statutory approvals. The Commission’s consultation on revised GMP Annex 11 and proposed AI Annex 22 closed on 7 October 2025. Final adoption of Annex 22 was not established in the reviewed sources; the current Volume 4 index still lists the January 2011 Annex 11. Treat the proposed text as draft, not an effective requirement. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile EudraLex — Volume 4 — Good Manufacturing Practice guidelines AI Risk Management Framework Stakeholders’ Consultation on EudraLex Volume 4 — Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22

10. Implementation roadmap and KPIs

A practical roadmap is use-case scoping → risk tiering → source and data architecture → controls → sandbox evaluation → human acceptance → monitored production → periodic revalidation. At scoping, define the output and accountable owner. In evaluation, include representative and adversarial cases, missing evidence, permissions failures and tool outages. Human acceptance should demonstrate that reviewers can identify consequential errors. Revalidation should also be triggered by material changes, not only a calendar interval. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products EudraLex — Volume 4 — Good Manufacturing Practice guidelines AI Risk Management Framework

Set baselines, denominators, severity categories and intervention thresholds for eight measures:

  • Source-verified accuracy: correct supported claims divided by sampled assessable claims.
  • Missed critical items: adjudicated critical items missed within the defined review sample.
  • Human override rate: materially changed or rejected recommendations, segmented by reason.
  • Time-to-review: elapsed time from an eligible input to accountable review completion.
  • Exception resolution: age and closure time of exceptions, with urgent items separately visible.
  • Unauthorized tool actions: blocked attempts and successful unauthorized actions tracked separately.
  • Audit-trail completeness: sampled tasks with all required evidence and event records.
  • Cost per validated task: total operating, integration, review and rework cost per accepted task.

Business value should reflect a quality-adjusted baseline, not token cost or draft speed alone. A falling override rate can mean improvement or reviewer complacency, so pair it with independent quality sampling. Do not set universal performance thresholds without the use-case risk assessment. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework

11. Frequently asked questions

Is agentic AI the same as generative AI?

No. Generative AI produces or transforms content; agentic AI coordinates work toward a goal using state, tools and feedback. They overlap when an agent uses a generative model to interpret evidence or propose actions. The distinction concerns system behavior and workflow responsibility, not a guarantee that one approach is more accurate or compliant. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile AI Risk Management Framework

Does agentic AI need an LLM?

Not as an absolute technical requirement. Goal-directed software can use planners, rules, search or other models. Many contemporary language-centered agents use LLMs because they handle variable instructions and evidence. In procurement, ask what component chooses actions and how execution is controlled rather than assuming an agent label identifies a specific model architecture.

Can GenAI be part of an agent?

Yes. A generative model may interpret a request, summarize retrieved evidence or propose a structured tool call. Workflow software and authorization controls then determine what happens. Treat model-generated calls as proposals requiring validation; the model should not create its own access rights or bypass approval simply because the requested action appears plausible. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile OWASP GenAI Security Project

When should pharma use rules instead?

Use rules for stable conditions, exact calculations, mandatory-field checks, access decisions and predefined routing where requirements can be expressed clearly. Rules still require testing and maintenance. Add generative interpretation only where language variability makes it useful, then verify that the additional complexity improves the complete process rather than merely making the interface conversational.

Can an AI agent submit regulatory filings?

It may assist assembly, checks and controlled technical transmission where the applicable process allows it. That is distinct from applicant authorization, required signatures and accountable scientific review. Bind approval to the actual package, version and destination; preserve acknowledgement and exception handling. No general AI architecture replaces legally assigned or procedure-specific filing responsibility. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products Part 11, Electronic Records; Electronic Signatures — Scope and Application

How do you validate agents for GxP use?

Define intended use and system boundaries, assess risk and establish acceptance criteria before testing. Evaluate the configured workflow, source handling, permissions, integrations, reviewer controls and failure paths. Retain evidence, manage changes and monitor production performance. A generic model benchmark or supplier assurance alone does not establish fitness for your particular regulated application. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products EudraLex — Volume 4 — Good Manufacturing Practice guidelines Part 11, Electronic Records; Electronic Signatures — Scope and Application

What is the biggest security risk?

There is no universal ranking for every deployment. A major agent-specific concern is untrusted content influencing a system that has consequential tool permissions. Prompt injection becomes more dangerous when paired with broad access or weak authorization. Reduce impact through least privilege, tool allowlists, isolation, validation and approval for sensitive actions, alongside monitoring and testing. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile OWASP GenAI Security Project

How do you measure business value?

Compare accepted, quality-checked work against a defined baseline. Include review time, rework, exceptions, integration and operating cost, not only generation speed. Track critical misses and unauthorized actions as guardrails. Cost per validated task and time to accountable review are more decision-useful than raw output volume when the business must rely on the result. AI Risk Management Framework

12. HERMS relevance

HERMS Global positions its portfolio around connected life-sciences intelligence across development, regulation, manufacturing, market access and safety. Domain-specific AI, traceable evidence, risk-based governance and human accountability are useful evaluation and design principles. This article does not establish that any named HERMS product has validated integrations, demonstrated performance or regulatory authorization. Those matters require deployment-specific evidence. AI Life Sciences Software | 25 HERMS Solutions

For the complementary discussion of approval boundaries, see “Agentic AI in Life Sciences: Which Decisions Can Be Automated—and Which Require Human Approval?” — INTERNAL_URL_TO_VERIFY (Blog 01; exact live URL not verified).

Explore HERMS Solutions and use the relevant solution enquiry to request a demonstration focused on your workflow, evidence and control requirements.

Relevant HERMS solutions

Explore HERMS solutions relevant to the workflows discussed in this article: SYNCRA — submission intelligence; AEVOX — safety case intake; VERIQIS — evidence integrity and assurance. Evaluate each solution against your intended use, evidence and approval requirements.

Sources and further reading

Explore HERMS life sciences solutions and AI governance and traceability, or request a workflow-focused demonstration.

FOR TECHNICAL ENQUIRIES,
CALL +971505528088

ENGINEERING INTELLIGENCE. REVOLUTIONIZING LIFE SCIENCES.

HERMS is the intelligence platform. Its applications are the decision engines. HERMS expert services support implementation and regulated execution of the HERMS intelligence ecosystem, from regulatory and market access to pharmacovigilance, compliance and quality.

Drug registration timelines by country · SFDA, MOHAP, EDE, EDA, EMA and FDA timelines · GCC central registration